ProSavin is an experimental drug believed to be of use in the treatment of Parkinson's disease . It is administered to the striatum in the brain , inducing production of dopamine .[ 1]
It is manufactured by Oxford BioMedica . Results from a Phase I/II clinical trial were published in the Lancet[ 2] [ 3] [ 4]
Mechanism of action
Prosavin uses Oxford BioMedica's Lentivector delivery system to transfer three genes, aromatic amino acid dopa decarboxylase , tyrosine hydroxylase and GTP-cyclohydrolase 1 , to the striatum in the brain, reprogramming transduced cells to secrete dopamine.[ 5] [ 6]
See also
References
^ Oxford BioMedica. Drug Information Page . Retrieved on March 29, 2007.
^ Palfi, Stéphane; Gurruchaga, Jean Marc; Ralph, G. Scott; Lepetit, Helene; Lavisse, Sonia; Buttery, Philip C.; Watts, Colin; Miskin, James; Kelleher, Michelle; Deeley, Sarah; Iwamuro, Hirokazu (2014-03-29). "Long-term safety and tolerability of ProSavin, a lentiviral vector-based gene therapy for Parkinson's disease: a dose escalation, open-label, phase 1/2 trial" . The Lancet . 383 (9923): 1138– 1146. doi :10.1016/S0140-6736(13)61939-X . ISSN 0140-6736 . PMID 24412048 . S2CID 4993549 . ^ Communications, Maggie Kuhl Director Research & CEO (28 January 2014). "ProSavin Trial Results: Once Again, a Gene Therapy Approach to Parkinson's Yields Encouraging Safety Data but Modest Efficacy | Parkinson's Disease" . www.michaeljfox.org . Retrieved 2021-04-09 . ^ Wexler, Marisa (20 August 2019). "Parkinson's Gene Therapy in Clinical Trial, AXO-Lenti-PD, Safe And Effective in Monkey Model of Disease, Study Says" . Retrieved 2021-04-09 . ^ "Positive results in Phase I/II trial" . OxfordBiomedica. 19 November 2008.^ "Prosavin" . OxfordBiomedica. Archived from the original on 16 March 2014.
